▪ a model for the "ectopic foci" theory of pain etiology by Marshall Devor PhD
▪ enables your candidate agent to show its biological efficacy for healing,
due to the lack of nerve damage.
▪ uses no irritant or trauma for initiation of "neuritis"
▪
no cutting of skin, breaking of bones, or wounds
▪
uses biocompatible collagen gel or hydrogels percutaneously▪ able to walk normally after procedure - no limping
▪ gradual onset of pain behavior >7days
▪ prolonged allodynia > 6mo.
▪ allodynia can be permanently reversed
▪ easily created in MICE
▪ easy to learn
percutaneous procedure
▪ high reliability of procedure - 95+%
▪ less numbers of animals needed (n=8 by power analysis)
▪ greater validity of drug testing
▪ months of research on the same subjects
The model demonstrates the sequelae of tissue repair after an injury which can cause neuritis,
persistent pain or Complex Regional Pain Syndrome I. This model demonstrates the initiation of neurogenic pain
behavior without direct trauma or an acute immune activation. The
development of immune activation occurs gradually with an increase in neural regeneration factors such as NGF and with the development of pain behavior,
just as persistent pain gradually develops after a soft tissue injury
in humans.
Biopharmaceuticals (such as recombinant human erythropoetin) have been shown to reverse these immune reactions with targeted applications.